| Men n = 2557 | Women n = 805 | P value |
---|---|---|---|
Age, years | 65.2 ± 7.7 | 62.6 ± 7.6 | < 0.001 |
Duration of COPD, years | 7.1 ± 5.2 | 7.7 ± 5.9 | 0.004 |
Current smoker, n (%) | 946 (37.0) | 387 (48.1) | < 0.001 |
Estimated number of pack years | 43.6 ± 22.5 | 36.0 ± 18.5 | < 0.001 |
Severity of COPD (GOLD 2015), n (%) | |||
 Low risk and more symptoms (Group B) | 589 (23.0) | 233 (28.9) | 0.002 |
 High risk and more symptoms (Group D) | 1945 (76.1) | 569 (70.7) | |
Severity of airflow limitation (GOLD 2011–2014), n (%) | |||
 Moderate (GOLD 2) | 804 (31.4) | 319 (39.6) | < 0.001 |
 Severe (GOLD 3) | 1506 (58.9) | 448 (55.7) | |
 Very severe (GOLD 4) | 222 (8.7) | 35 (4.3) | |
Pre-bronchodilator FEV1, L | 1.1 ± 0.3 | 0.8 ± 0.2 | < 0.001 |
Post-bronchodilator FEV1, L | 1.3 ± 0.3 | 1.0 ± 0.3 | < 0.001 |
Post-bronchodilator FEV1, % predicted | 43.5 ± 9.5 | 45.8 ± 9.0 | < 0.001 |
Post-bronchodilator FEV1 reversibility, % of baseline value | 22.2 ± 16.0 | 22.9 ± 16.2 | 0.233 |
Post-bronchodilator FEV1/FVC, % | 40.9 ± 9.9 | 43.7 ± 9.5 | < 0.001 |
Number of COPD exacerbations in the previous year, n (%) | |||
 1 | 2094 (81.9) | 616 (76.5) | 0.002 |
 ≥ 2 | 461 (18.0) | 188 (23.4) | |
CAT scorea | 16.5 ± 7.0 | 17.7 ± 7.1 | < 0.001 |
mMRCb, n (%) | |||
 Grade 0–1 | 4 (0.2) | 1 (0.1) | 0.954 |
 Grade 2 | 1838 (71.9) | 574 (71.3) | |
 Grade 3 | 660 (25.8) | 211 (26.2) | |
 Grade 4 | 55 (2.2) | 19 (2.4) | |
BMI (kg/m2) | 25.7 ± 4.9 | 26.3 ± 6.0 | 0.003 |
ICS use, n (%) | 1382 (54.0) | 511 (63.5) | < 0.001 |
LAMA use, n (%) | 1535 (60.0) | 502 (62.4) | 0.238 |
LABA use, n (%) | 1651 (64.6) | 606 (75.3) | < 0.001 |